Miguel Debono1, Mike Bradburn, Matthew Bull, Barney Harrison, Richard J Ross, John Newell-Price. 1. Academic Unit of Endocrinology, Department of Human Metabolism (M.D., R.J.R., J.N.-P.), University of Sheffield, South Yorkshire S10 2RX, United Kingdom; Medical Statistics and Clinical Trials Research Unit (M.Br.), The School of Health and Related Research, University of Sheffield, South Yorkshire S1 4DA, United Kingdom; The Departments of Endocrinology (M.D., R.J.R., J.N.-P.), Radiology (M.Bu.), and Endocrine Surgery (B.H.), Royal Hallamshire Hospital, Sheffield Teaching Hospitals National Health Service Foundation Trust, South Yorkshire S10 2JF, United Kingdom.
Abstract
CONTEXT: Incidental benign adrenocortical adenomas, adrenal incidentalomas are found in 4.5% of abdominal computed tomography scans, with the incidence increasing to 10% in patients older than 70 years of age. These incidentalomas frequently show evidence of excess cortisol secretion but without overt Cushing's syndrome. The mortality rate is increased in Cushing's syndrome. OBJECTIVE: This study sought to investigate whether patients with adrenal incidentalomas have an increased mortality. DESIGN: This was a retrospective, longitudinal cohort study. SETTING: The study was carried out in an Endocrine Investigation Unit in a University Teaching Hospital. PATIENTS: Two hundred seventy-two consecutive patients with an incidental adrenal mass underwent a dedicated diagnostic protocol, which included dexamethasone testing for hypercortisolism between 2005 and 2013. Overall survival was assessed in 206 patients with a benign, adrenocortical adenoma. MAIN OUTCOME MEASURES: Survival analysis was carried out by using Kaplan-Meier curves and the effect of dexamethasone cortisol estimated by Cox-regression analysis. Cause-specific mortality was ascertained from death certificates and compared with local and national data. RESULTS: Eighteen of 206 patients died and the mean time (SD) from diagnosis to death was 3.2 (1.7) years. Seventeen of 18 patients who died had a post dexamethasone cortisol >1.8 μg/dL and there was a significant decrease in survival rate with increasing dexamethasone cortisol levels (P = .001). Compared with the <1.8 μg/dL group, the hazard ratio (95% confidence interval) for the 1.8-5 μg/dL group was 12.0 (1.6-92.6) whereas that of the >5 μg/dL group was 22.0 (2.6-188.3). Fifty percent and 33% of deaths were secondary to circulatory or respiratory/infective causes, respectively. CONCLUSIONS: PATIENTS with adrenal incidentalomas and a post-dexamethasone serum cortisol >1.8 μg/dL have increased mortality, mainly related to cardiovascular disease and infection.
CONTEXT: Incidental benign adrenocortical adenomas, adrenal incidentalomas are found in 4.5% of abdominal computed tomography scans, with the incidence increasing to 10% in patients older than 70 years of age. These incidentalomas frequently show evidence of excess cortisol secretion but without overt Cushing's syndrome. The mortality rate is increased in Cushing's syndrome. OBJECTIVE: This study sought to investigate whether patients with adrenal incidentalomas have an increased mortality. DESIGN: This was a retrospective, longitudinal cohort study. SETTING: The study was carried out in an Endocrine Investigation Unit in a University Teaching Hospital. PATIENTS: Two hundred seventy-two consecutive patients with an incidental adrenal mass underwent a dedicated diagnostic protocol, which included dexamethasone testing for hypercortisolism between 2005 and 2013. Overall survival was assessed in 206 patients with a benign, adrenocortical adenoma. MAIN OUTCOME MEASURES: Survival analysis was carried out by using Kaplan-Meier curves and the effect of dexamethasone cortisol estimated by Cox-regression analysis. Cause-specific mortality was ascertained from death certificates and compared with local and national data. RESULTS: Eighteen of 206 patients died and the mean time (SD) from diagnosis to death was 3.2 (1.7) years. Seventeen of 18 patients who died had a post dexamethasone cortisol >1.8 μg/dL and there was a significant decrease in survival rate with increasing dexamethasone cortisol levels (P = .001). Compared with the <1.8 μg/dL group, the hazard ratio (95% confidence interval) for the 1.8-5 μg/dL group was 12.0 (1.6-92.6) whereas that of the >5 μg/dL group was 22.0 (2.6-188.3). Fifty percent and 33% of deaths were secondary to circulatory or respiratory/infective causes, respectively. CONCLUSIONS: PATIENTS with adrenal incidentalomas and a post-dexamethasone serum cortisol >1.8 μg/dL have increased mortality, mainly related to cardiovascular disease and infection.
Authors: G Ntali; A Asimakopoulou; T Siamatras; J Komninos; D Vassiliadi; M Tzanela; S Tsagarakis; A B Grossman; J A H Wass; N Karavitaki Journal: Eur J Endocrinol Date: 2013-10-08 Impact factor: 6.664
Authors: J Lindholm; S Juul; J O Jørgensen; J Astrup; P Bjerre; U Feldt-Rasmussen; C Hagen; J Jørgensen; M Kosteljanetz; L Kristensen; P Laurberg; K Schmidt; J Weeke Journal: J Clin Endocrinol Metab Date: 2001-01 Impact factor: 5.958
Authors: Nicole Vogelzangs; Aartjan T F Beekman; Yuri Milaneschi; Stefania Bandinelli; Luigi Ferrucci; Brenda W J H Penninx Journal: J Clin Endocrinol Metab Date: 2010-08-25 Impact factor: 5.958
Authors: M J H J Dekker; J W Koper; M O van Aken; H A P Pols; A Hofman; F H de Jong; C Kirschbaum; J C M Witteman; S W J Lamberts; H Tiemeier Journal: J Clin Endocrinol Metab Date: 2008-08-05 Impact factor: 5.958
Authors: Antonio Toniato; Isabella Merante-Boschin; Giuseppe Opocher; Maria R Pelizzo; Francesca Schiavi; Enzo Ballotta Journal: Ann Surg Date: 2009-03 Impact factor: 12.969
Authors: F Pugliese; A S Salcuni; C Battista; V Carnevale; G Guglielmi; C Columbu; F Velluzzi; L Giovanelli; C Eller-Vainicher; A Scillitani; I Chiodini Journal: Endocrine Date: 2021-01-23 Impact factor: 3.633
Authors: Andrew D Frugé; Mallory G Cases; Carrie R Howell; Yuko Tsuruta; Kelley Smith-Johnston; Douglas R Moellering; Wendy Demark-Wahnefried Journal: Cancer Causes Control Date: 2017-11-23 Impact factor: 2.506